Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Trading under new ticker symbol "BAXS" to begin June 3, 2013 Completes financing of $17.2M at $2.28/share Two directors and Vice President of Operations appointed from former Baxano, Inc...
- First quarter revenues were $3.1 million - - Net loss per share was $0.26 for the quarter - - Excluding special items, net loss per share was $0.21 for the quarter* - - Acquisition of...
RALEIGH, N.C., April 26, 2013 (GLOBE NEWSWIRE) -- TranS1 Inc. (Nasdaq:TSON) announced today that it plans to release first quarter 2013 financial and operating results, and provide an update on...
RALEIGH, N.C., March 14, 2013 (GLOBE NEWSWIRE) -- TranS1 Inc. (Nasdaq:TSON) announced today that it will participate in the Canaccord Genuity Musculoskeletal conference in March. Ken Reali...
Conference Call to be Held on March 4, 2013 at 8:30 a.m. EST Combination Adds Rapidly Growing Minimally Invasive Spinal Decompression Technology and Large Surgeon User Base Baxano...
WILMINGTON, N.C., Feb. 21, 2013 (GLOBE NEWSWIRE) -- TranS1 Inc. (Nasdaq:TSON) announced today that it will participate in two healthcare conferences in February and March, 2013. Ken Reali...
WILMINGTON, N.C., Feb. 20, 2013 (GLOBE NEWSWIRE) -- TranS1 Inc. (Nasdaq:TSON) announced today that it plans to release fourth quarter 2012 financial and operating results after market close on...
WILMINGTON, N.C., Feb. 19, 2013 (GLOBE NEWSWIRE) -- TranS1 Inc. (Nasdaq:TSON), a medical device company focused on designing, developing and marketing spine products to treat degenerative...
WILMINGTON, N.C., Feb. 11, 2013 (GLOBE NEWSWIRE) -- TranS1 Inc. (Nasdaq:TSON), a medical device company focused on designing, developing and marketing products to treat degenerative conditions of...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
